BIEL Upgraded to OTCID — The Old Book Is CLOSED. The New

New Post Public Reply Private Reply Replies (0) Message Board
Bielionaire
223
BIEL Upgraded to OTCID — The Old Book Is CLOSED. The New BIEL Story Is a BLOCKBUSTER.

1. The 2024–2025 Financials Are IRRELEVANT — Totally Meaningless — and OTCID Just Proved It
The old numbers? Who cares.
Yes, revenue went from $496,032 to $510,623 and COGS dropped from $132,633 to $77,276 — very nice, very cute numbers for the old BIEL .

But those numbers belong to the prehistoric era — before Electrome, before Haleon, before Veterinary AI.  They’re from the dead model, the “standalone device seller” days.

And now BIEL is upgraded to OTCID, which means:
Verified disclosures
Real transparency
Real oversight
Real legitimacy

OTCID is the market saying:
“The old financials don’t matter. This is a NEW company now.”

Because BIEL is no longer a gadget company — it’s the exclusive hardware engine for an AI‑native therapeutics ecosystem across human, veterinary, and global consumer health .

Electrome AI is the brain.
BIEL PEMF is the engine.
Intel Inside — but for pain, recovery, and performance.

The pivot just happened.
The old revenue is totally meaningless now.

2. The OEM Future Is MASSIVE — We’re Talking Millions, Not Pennies
Three OEM engines.
Three multi‑million‑dollar verticals.
All rolling out NOW — not in 2035.

OEM Engine #1 — Electrome (Human Health)
$0.75M–$2.25M early
$4M–$7M expansion
$7.5M–$22M national rollout

OEM Engine #2 — Veterinary AI
$500K–$1.2M elite animals
$3M–$7.5M specialty clinics
$12M–$25M+ global pet wearables

OEM Engine #3 — Haleon (Global Consumer Health)
$2M–$5M pilots
$15M–$35M rollout
$50M–$100M+ mass‑market wearables

Compared to this?  The 2024–2025 financials are rounding errors.

OTCID makes these numbers even more powerful because now institutions, brokers, and OEM partners can take BIEL seriously.

3. Capital Factory Validation — The Big Leagues Only
Electrome is backed by Capital Factory, one of the most respected VC groups in the U.S.  

Their involvement means:
The tech is real
The platform is scalable
BIEL is locked in as the hardware engine
Microcaps NEVER get this kind of validation.
BIEL did.

Once institutional validation enters the picture, the old micro‑revenues are irrelevant — future cash flows matter now.

OTCID reinforces this.
It’s the “grown‑up table.”
And BIEL just got a seat.

4. The Float, Momentum, and AI Narrative Are a Powder Keg — OTCID Just Lit the Fuse:
A 400% run from .0001 to .0005
A vanishing float
A pending supply squeeze

This is EXACTLY what happens before microcaps explode.  And the AI narrative?  Electrome turns BIEL into a hot‑sector AI hardware play.  The market prices the future, not the past.  

OTCID amplifies all of this:
More brokers allow buying
More investors gain access
More liquidity
More demand
Same tiny float
Boom.

5. Profitability Is Close — And the Model Is Lean, Lean, LEAN
BIEL already proved profitability:
Q3 2021 profit: $22,381 on $414,700 revenue
COGS is now dramatically lower.
OEM volumes are rising.
Profitability is right there.
And the $40M tax loss carryforward?  That’s a rocket booster for net profit conversion.

OTCID makes all of this more visible, more credible, more investable.

6. PPS Re‑Rating Scenarios — The Old Numbers Don’t Matter

PPS Projections corresponding to hitting milestones:
.001 — Technical breakout
.01 — Cash‑flow positive (est. $1.5M revenue)
.04 — $1M profit
.10 — $2.5M profit (est. $3M revenue, P/E 1000)
$1.00 — After debt payoff + buyback

These valuations are based on future OEM profit, not legacy device sales.

OTCID makes these targets more realistic because:
More buyers
More legitimacy
Higher multiples
Better visibility

7. The Old Story Is Over — The New One Is a Monster
The old financials don’t define BIEL — they’re the last pages of the old story.  

The new story is:
AI‑native therapeutics
Multi‑industry OEM dominance
VC validation
Global consumer health
Veterinary expansion
Recurring hardware nodes
A closed‑loop ecosystem

BIEL is no longer a $500K company — it’s a future $100M+ OEM engine.

The past is irrelevant.  The future is asymmetric!

8. The “Startup Without Startup Risk”

Five FDA clearances
Validated manufacturing
VC backing
No burn rate
No R&D drag
No regulatory uncertainty

Instead of spending $50M–$100M on development and trials, BIEL already has it all — plus patents pending, including vagus nerve modulation .

This is the rare microcap with:
A regulatory moat
An IP pipeline
A VC‑funded commercialization engine
BEFORE revenue inflection even begins
OTCID makes this narrative even stronger.

CONCLUSION
BIEL just got upgraded to OTCID.

That means the market sees what the bashers don’t:
This is NOT the old BIEL.
This is a NEW company with REAL partners, REAL OEM engines, REAL AI integration, REAL VC backing, and REAL scale ahead.

The old book is closed.  The new book is a bestseller.

And the people who don’t get it?
They’re going to get left behind.  BYE BYE! (or BUY BUY?)

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 114

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 7

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 172

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 215

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 66

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 207

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 26

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading

Top 5 Most Recently Viewed Articles

Alliance Entertainment Expands Leadership with Robert Oram

Updated Category News Views 137

Alliance Entertainment Welcomes Robert Oram as EVP Alliance Entertainment Holding Corporation (NASDAQ: AENT) has made a significant addition to its leadership team with the appointment of Robert Oram as the Executive Vice President. This strategic move, announced recently, aims to bolster the company's efforts in expanding its home entertainment division. Oram, a veteran...

Continue Reading
Teradyne Inc: Navigating AI Growth in Semiconductor Testing

Updated Category News Views 155

Teradyne Inc (NASDAQ: TER) was one of those stocks that had traders buzzing back in 2023 when it saw gains up to 50% early in the year. That kind of momentum, especially outpacing the Philadelphia Semiconductor Index, had folks dreaming big. But reality hit later on as the market pulled back, reminding everyone that nothing lasts forever in this volatile game. Market...

Continue Reading
Transforming Landscapers' Cash Flow with Duranta's Payments

Updated Category News Views 163

Duranta Unveils a Game-Changer for Landscapers' Payments Duranta, the AI-driven platform for landscaping professionals, is set to reshape how landscaping businesses handle payments. Recently, they introduced an innovative feature that embeds secure payment links directly into customer invoices. This new function streamlines transaction methods for landscapers, making it...

Continue Reading
Analyzing Market Trends: The Case of WR Berkley Stock

Updated Category News Views 146

Understanding WR Berkley and Its Market Position WR Berkley Corporation (NYSE: WRB) has been making headlines recently due to its fluctuating short interest levels. The company, known for its diverse insurance offerings, recorded a significant rise in its short percent of float, now standing at 22.48%. This figure comes from its recent announcement that approximately 7.96...

Continue Reading
Timbercreek Financial to Host Q4 Results Call - Key Details Inside

Updated Category News Views 153

Timbercreek Financial's Upcoming Conference Call Timbercreek Financial (TSX: TF) is gearing up for an important conference call to discuss its financial results for the last quarter. This call is set for 1:00 p.m. (ET) on a Wednesday. The insights into the company’s performance will be revealed shortly after the markets close. Stakeholders and interested parties are...

Continue Reading